Intracellular NAD+ Assessment

Intracellular NAD+ Assessment — Cellular Energy Currency and Longevity Cofactor Quantification (SGD 600)

The Intracellular NAD+ Assessment is EMIS+'s dedicated quantification of nicotinamide adenine dinucleotide (NAD+) — the central metabolic cofactor and electron carrier whose intracellular concentration declines approximately 50% between ages 20 and 70, mechanistically impairing the activity of sirtuins (SIRT1–7), poly-ADP-ribose polymerases (PARP1/2), and CD38 NADase — three enzyme families governing DNA repair fidelity, mitochondrial biogenesis, circadian rhythm entrainment, and inflammatory resolution. Measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) from peripheral blood mononuclear cells (PBMCs), the assessment provides absolute intracellular NAD+ concentration (pmol/mg protein), the NAD+/NADH redox ratio, and NAMPT (nicotinamide phosphoribosyltransferase) enzyme activity — the rate-limiting step of NAD+ biosynthesis via the salvage pathway. Results are benchmarked against an age/sex-stratified normative reference database to yield an NAD+ Depletion Index and biological age-equivalent NAD+ status.

NAD+ Biology and Age-Related Decline: NAD+ functions simultaneously as a redox carrier in oxidative phosphorylation (NADH → NAD+ in the electron transport chain, Complex I) and as a substrate for non-redox signalling enzymes. The sirtuins (SIRT1–7) — class III histone deacylases requiring NAD+ stoichiometrically — are activated when NAD+ is abundant and silenced when NAD+ falls below a critical threshold (~100 µM intracellular). SIRT1 and SIRT3 regulate mitochondrial biogenesis via PGC-1α deacetylation; SIRT6 maintains telomere stability and DNA double-strand break repair; SIRT1 modulates the BMAL1/CLOCK circadian transcription complex. PARP1, the primary DNA damage sensor, consumes NAD+ per ADP-ribosylation event — in the context of excessive DNA damage (from oxidative stress, UV, ionising radiation), PARP hyperactivation can deplete cellular NAD+ within minutes, creating a bioenergetic crisis. CD38 — a multifunctional ectoenzyme expressed on immune cells — is the dominant NAD+ consumer in aged tissue, with CD38 expression increasing 2–3× between ages 25–70 (Camacho-Pereira et al., Cell Metabolism 2016), explaining the paradox of reduced NAD+ despite adequate dietary precursor intake.

Measurement Methodology — LC-MS/MS: PBMC isolation from fresh venous blood (within 2 hours, standardised collection protocol) is performed by Ficoll density-gradient centrifugation. Cell pellets are lysed in perchloric acid to terminate metabolic activity, and the lysate is processed by reverse-phase LC-MS/MS using isotope-labelled internal standards (¹³C₅-NAD+) for absolute quantification. This method achieves an analytical sensitivity of 0.5 pmol/mg protein with inter-assay CV <8%. The NAD+/NADH ratio is calculated from simultaneous LC-MS/MS quantification of reduced NADH. NAMPT activity is measured by a fluorometric enzymatic cycling assay detecting nicotinamide mononucleotide (NMN) production rate (nmol NMN/hr/mg protein). The PBMC-based measurement reflects the intracellular NAD+ status of circulating immune cells — the most accessible surrogate for systemic NAD+ homeostasis, validated against tissue biopsies in the Rajman et al. framework (Cell Metabolism 2018).

NAD+ Depletion Index and Clinical Risk Stratification: The NAD+ Depletion Index integrates absolute NAD+ concentration percentile rank, NAD+/NADH ratio deviation from age-matched norm, and NAMPT activity z-score into a composite deprivation metric. An Index ≥+1.5 SD below age-matched mean identifies individuals whose sirtuin and PARP activity is likely substrate-limited — where NAD+ precursor supplementation (NMN or NR at doses of 300–1000 mg/day) is supported by Phase I/II human trial evidence. Irie et al. (npj Aging and Mechanisms of Disease 2020) demonstrated that oral NMN 250 mg/day for 12 weeks significantly increased whole blood NAD+ in healthy older adults (mean age 65, p<0.001 vs. placebo). Dolopikou et al. (European Journal of Nutrition 2020) showed NR 1000 mg/day increased PBMC NAD+ by 2.7× over 21 days. The assessment enables pre/post supplementation monitoring to confirm individual pharmacological response — essential given the 3–5× inter-individual variability in NAD+ biosynthetic capacity documented in the Yoshino et al. CELL 2021 study.

Combination with EMIS+ Longevity Panel: The Intracellular NAD+ Assessment integrates with EMIS+ TrueAge epigenetic clocks, Cellular Senescence Dual-Panel, and EMIS+ Longevity Core for a complete mechanistic longevity map: epigenetic clock → rate of biological age accumulation; Cellular Senescence Dual-Panel → senescent cell burden driving SASP; NAD+ Assessment → sirtuin and PARP substrate availability driving DNA repair and circadian fidelity. Low NAD+ in the context of high p16INK4a/SASP identifies a senescence-associated NAD+ depletion phenotype (Chini et al., Cell Reports 2020) where combined senolytic + NAD+ precursor therapy is mechanistically additive.

Q1: Why is intracellular PBMC NAD+ measurement superior to whole-blood or plasma NAD+ for clinical decision-making?

Whole-blood NAD+ is dominated by erythrocyte NAD+ — which reflects red blood cell redox metabolism rather than the nuclear/mitochondrial NAD+ pool governing sirtuin and PARP activity. Erythrocytes lack nuclei and mitochondria, making their NAD+ content irrelevant to the transcriptional and DNA repair functions that decline with age. Plasma NAD+ is present at picomolar concentrations — far below the intracellular millimolar range where enzyme kinetics operate — and reflects extracellular NAD+ flux rather than cellular substrate availability. PBMC-based intracellular measurement — after PBMC isolation and protein-precipitation cell lysis — directly quantifies the NAD+ concentration available to nuclear SIRT1/SIRT6, mitochondrial SIRT3, and PARP1 within the cells most reflective of systemic immune and metabolic ageing. The Rajman, Chwalek and Sinclair Cell Metabolism 2018 review establishes PBMC NAD+ as the clinically validated surrogate measure for NAD+ precursor trial monitoring, as used in the Irie 2020 NMN trial and Yoshino 2021 CELL study. EMIS+ uses the PBMC LC-MS/MS methodology aligned with these published human trial protocols for direct result comparability.

Q2: What is NAMPT, and why does its activity measurement add clinical value beyond NAD+ concentration alone?

Nicotinamide phosphoribosyltransferase (NAMPT) catalyses the rate-limiting first step of the NAD+ salvage pathway — the conversion of nicotinamide (NAM) to nicotinamide mononucleotide (NMN), which is then converted to NAD+ by NMNAT enzymes. NAMPT activity determines an individual's endogenous NAD+ biosynthetic ceiling independent of dietary precursor availability. Two distinct NAD+ depletion phenotypes exist: (1) NAMPT-limited: reduced NAMPT activity constrains NAD+ production even when precursor availability is adequate — NMN supplementation (bypassing the NAMPT step by providing NMN directly) is preferred over NR (which requires NAMPT to convert NAM back to NMN via the salvage pathway); (2) Substrate-limited: adequate NAMPT activity but inadequate dietary NAM/NR/NMN precursor intake — either NR or NMN supplementation is effective. Without NAMPT measurement, NR supplementation may be ineffective in NAMPT-limited individuals, explaining the significant inter-individual variation in NAD+ response reported by Yoshino et al. (Cell 2021). The NAMPT activity assay in the EMIS+ Intracellular NAD+ Assessment enables precision-guided precursor selection — a clinically meaningful distinction given the cost differential between NMN (approximately USD 1–3 per 500mg dose) and NR (approximately USD 0.5–1.5 per 250mg dose) at therapeutic doses.

Q3: What is the current Phase I/II human clinical evidence for NMN and NR supplementation raising intracellular NAD+?

Multiple randomised, placebo-controlled human trials confirm oral NMN and NR supplementation raises intracellular NAD+ in peripheral blood cells. Key evidence: (1) Irie et al. npj Aging and Mechanisms of Disease (2020): NMN 250 mg/day for 12 weeks in healthy older adults (mean age 65) increased whole blood NAD+ significantly vs. placebo (p<0.001); muscle insulin sensitivity and physical performance (grip strength, walking speed) improved in the highest-baseline-NAD+-response subgroup. (2) Yoshino et al. Cell (2021): NMN 250 mg/day for 10 weeks in postmenopausal women with prediabetes increased muscle NAD+ content and improved insulin-stimulated glucose disposal, demonstrating tissue-level functional NAD+ restoration. (3) Dolopikou et al. European Journal of Nutrition (2020): NR 1000 mg/day in older adults (mean age 73) for 21 days increased PBMC NAD+ 2.7× vs. baseline, with significant reduction in inflammatory markers including IL-6. (4) Martens et al. Nature Communications (2022): NR 1000 mg/day for 6 weeks in healthy middle-aged/older adults significantly raised blood NAD+ metabolome, reduced arterial stiffness and blood pressure. (5) Elhassan et al. Cell Reports (2019): NR 1000 mg/day elevated NAD+ metabolism in skeletal muscle, liver, and adipose tissue with concurrent SIRT1/SIRT3 activation markers. The EMIS+ assessment provides the pre-supplementation NAD+ baseline necessary to confirm a below-threshold status before initiating supplementation, and the post-supplementation follow-up assessment to confirm individual response.

Q4: How do sirtuins depend on NAD+, and which sirtuin functions are most impacted by age-related NAD+ decline?

Sirtuins (SIRT1–7) are class III NAD+-dependent protein deacylases that consume one molecule of NAD+ per deacylation reaction, producing nicotinamide (NAM) and O-acetyl-ADP-ribose as by-products. Because sirtuins are kinetically dependent on NAD+ concentration rather than simply requiring its presence as a cofactor, their activity falls proportionally as intracellular NAD+ declines with age. SIRT1 (nuclear/cytoplasmic): deacetylates PGC-1α (activating mitochondrial biogenesis and oxidative phosphorylation), p53 (suppressing senescence and apoptosis), and the BMAL1/CLOCK complex (maintaining circadian rhythm amplitude). SIRT1 loss drives circadian disruption, accelerated epigenetic ageing, and impaired stress resistance. SIRT3 (mitochondrial matrix): deacetylates and activates Complex I (NADH dehydrogenase), Complex II, and antioxidant enzymes (SOD2/MnSOD), reducing mitochondrial ROS production. SIRT3 knockout mice show accelerated metabolic syndrome, hearing loss, and cardiac fibrosis. SIRT6 (nuclear chromatin): maintains telomere structure by deacetylating H3K9 and H3K56 at telomere regions, and promotes double-strand break repair by recruiting DNA-PKcs. SIRT6 deficiency in mice produces premature ageing phenotypes including lordokyphosis, metabolic syndrome, and shortened lifespan. SIRT7 (nucleolar): regulates ribosomal RNA transcription and proteostasis. Age-related NAD+ decline simultaneously impairs all seven sirtuins, explaining why NAD+ depletion phenotypes manifest as multisystem biological age acceleration rather than a single-organ phenotype.

Q5: How should the Intracellular NAD+ Assessment results be interpreted alongside exercise and dietary interventions before initiating NMN/NR supplementation?

Before initiating NMN or NR supplementation, the Intracellular NAD+ Assessment report evaluates whether lifestyle-accessible NAD+ optimisation has been maximised. Endurance exercise robustly upregulates NAMPT expression in skeletal muscle (Costford et al., J Physiol 2010; Canto et al., Cell 2010) — individuals who are sedentary (fewer than 75 minutes vigorous or 150 minutes moderate aerobic activity per week per ACC/AHA guidelines) may achieve clinically significant NAD+ restoration through exercise alone without supplementation. Caloric restriction and time-restricted eating (16:8 TRE) activate AMPK, suppressing mTORC1 and CD38 expression — reducing NAD+ consumption and allowing recovery. Niacin (vitamin B3, NAM) dietary adequacy is the primary precursor assessment: individuals with dietary intake below the RDA of 16 mg NE/day (adult male) or 14 mg NE/day (adult female) will show NAMPT-substrate depletion correctable with dietary optimisation before considering supplemental NMN/NR. The NAD+ Depletion Index threshold for supplementation recommendation is calibrated at ≥1.5 SD below age-matched mean — a level at which lifestyle optimisation alone has been insufficient in the CALERIE-2 and HERITAGE family study data to restore NAD+ to age-appropriate levels, and where Phase II trial evidence (Irie 2020; Yoshino 2021) demonstrates supplemental NMN/NR provides additional, measurable restoration. The post-supplementation follow-up assessment at 6–12 weeks objectively confirms individual response, enabling dose titration or alternative precursor switching (NMN vs. NR) based on measured intracellular NAD+ change.

Regulatory and Methodological Framework: The Intracellular NAD+ Assessment is performed within an ISO 15189:2022-accredited laboratory with CAP external quality assurance and Singapore HSA laboratory licensing. LC-MS/MS NAD+ quantification uses isotope dilution methodology (¹³C₅-NAD+ internal standard) traceable to NIST Standard Reference Material 8327 (nucleotide quantification) with inter-assay CV <8% and intra-assay CV <5%. PBMC isolation follows standardised Ficoll-Paque Plus (1.077 g/mL) density gradient centrifugation with cold-chain preservation (2–8°C) from blood draw to cell lysis within 2 hours, consistent with the PBMC processing protocol validated in Irie et al. 2020 and Yoshino et al. 2021. NAMPT enzymatic activity assay uses a fluorometric cycling method with NMN fluorescence detection, calibrated against purified recombinant human NAMPT (specific activity reference). The NAD+ Depletion Index normative database is constructed from age/sex-stratified PBMC NAD+ values from healthy non-smoking, non-diabetic adults aged 25–75, referenced to the age-related decline trajectory described in Camacho-Pereira et al. Cell Metabolism 2016 and Massudi et al. PLoS ONE 2012. Supplementation guidance references the NIA-funded NMN and NR human clinical trial evidence base through 2024 publication cutoff. NMN and NR are classified as health supplements in Singapore and are not registered as therapeutic products under the Singapore Health Sciences Authority Therapeutic Products Act. Advice regarding NMN/NR supplementation is provided as nutritional health information; therapeutic intervention decisions remain the purview of licensed Singapore MOH-registered physicians.